Policy & Regulation

Rescheduling may bring long-awaited 280E relief and a new sheen of mainstream legitimacy, but it also opens the door to federal-grade oversight, GMP expectations, stricter lender requirements, and expanded liability exposure. The “extra” cash operators anticipate could be quickly absorbed by compliance upgrades, professional services, and risk management. For CEOs, COOs, and CFOs, reclassification isn’t a finish line. It’s the starting gun for a tougher operational race.

What cannabis rescheduling to Schedule III really means, how the process works, and why it matters for businesses and patients.

Rescheduling marijuana from Schedule I to Schedule III would not legalize cannabis — but it could fundamentally alter how the federal government treats the plant. From tax policy and medical research to regulatory oversight, here’s what cannabis rescheduling actually means, how the process works, and why it matters to businesses, patients, and policymakers.

President Donald Trump signed an executive order directing the Attorney General to expedite the rescheduling of marijuana from Schedule I to Schedule III — a move that could eliminate 280E taxation for cannabis businesses but still requires formal DEA rulemaking. While the White House framed the order as “common sense,” opposition from congressional Republicans and unresolved administrative hearings leave the timeline uncertain.

Wyoming’s U.S. attorney said marijuana possession on federal lands will face strict prosecution under revised Justice Department guidance.

New polling shows most Canadians want Ottawa to support legal cannabis as an economic opportunity, not just a regulatory issue.

More than 150 licensed dispensaries in New York won’t face forced closure or relocation after a state Supreme Court injunction blocked OCM’s reinterpretation of school-zone rules.

As global cannabis standards solidify, U.S. operators have a narrow window to align, adapt, and reclaim leadership in international markets.

The House Appropriations Committee voted September 10 on provisions that could upend federal cannabis policy. Tucked into the fiscal year 2026 Commerce-Justice-Science bill are riders that block the DEA from completing its rescheduling review and weaken long-standing protections for state medical programs.

For 88 years, cannabis prohibition has been propped up by fear, falsehoods, and prejudice. Today, most Americans support legalization — and the clock is ticking on this failed policy.